Analytical Data
-
Gene name
BIRC6
- Application
-
Alternative Names
BRUCE; Apollon; BIR repeat-containing ubiquitin-conjugating enzyme; Ubiquitin-conjugating BIR domain enzyme apollon
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9NR09
-
Expression Region
Arg4576~Leu4857
-
Molecular Weight
40kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BIRC6, a member of the inhibitors of apoptosis (IAP) gene family, plays a critical role in regulating cellular apoptosis and ensuring cell survival under various stress conditions. Research has shown that BIRC6 is overexpressed in several types of cancer, including ovarian and breast cancers, where it contributes to tumor progression by inhibiting caspases, the key enzymes responsible for mediating apoptosis. Due to its pro-survival function, BIRC6 has become a potential target for therapeutic intervention, particularly in cancer treatments aimed at restoring apoptotic pathways to induce cell death in malignant cells. The production of recombinant BIRC6 protein is essential for understanding its structure-function relationships and interactions with other cellular proteins. This knowledge can aid in the development of small molecules or antibodies that can disrupt BIRC6's interaction with caspases or other apoptotic factors, thereby enhancing the efficacy of existing chemotherapy treatments. Additionally, studying the post-translational modifications of BIRC6 can provide insights into its regulatory mechanisms and biological significance in both normal and pathological conditions. The recombinant BIRC6 protein serves as a valuable tool in elucidating these mechanisms and potentially identifying novel therapeutic strategies targeting aberrant apoptosis in cancers. Overall, the investigation of BIRC6 through recombinant protein technology highlights its significance in cancer biology and opens new avenues for targeted therapies aimed at overcoming apoptosis resistance in tumor cells.
